Castle Biosciences (CSTL) Q2 2024 earnings summary

Executive summary

• Q2 2024 revenue rose 74% year-over-year to $87 million, with total test report volume up 49% to 25,102, driven by strong growth across dermatology, gastroenterology, and mental health portfolios.

• Net income for Q2 2024 was $8.9 million, reversing a net loss of $18.8 million in Q2 2023, reflecting improved operating leverage and revenue growth.

• The company focuses on innovative diagnostic tests in dermatology, gastroenterology, mental health, and ophthalmology, targeting high unmet clinical needs and significant market opportunities.

• Full-year 2024 revenue guidance increased to $275–300 million from $255–265 million, reflecting 25%-36% year-over-year growth.

• Strong performance attributed to differentiated portfolio, robust clinical evidence, and disciplined execution of growth initiatives.

Financial highlights

• Q2 2024 net revenues: $87.0 million, up 74% year-over-year; adjusted revenues were $86.6 million, up 72%.

• Gross margin improved to 80.7% from 73.5% year-over-year; adjusted gross margin rose to 83.2% from 78%.

• Net income reached $8.9 million, compared to a net loss of $18.8 million in Q2 2023.

• Adjusted EBITDA was $21.5 million, up from -$5.3 million in Q2 2023.

• Cash, cash equivalents, and marketable securities totaled $259.7 million at quarter end.

Outlook and guidance

• 2024 revenue guidance raised to $275–300 million, up from $255–265 million, reflecting strong H1 performance.

• Management expects continued commercial momentum, robust test volume growth, and portfolio expansion, with a focus on pipeline test launches and evidence development.

• Guidance assumes no CMS coverage for DecisionDx-SCC in Q4 2024 and no change in ASP.

• Long-term guidance for 2025 assumes no SCC coverage but expects positive adjusted operating cash flow.

• Existing cash, equivalents, and anticipated product sales are expected to fund operations for at least the next 12 months.